Sex and Gender Differences in Anticancer Treatment Toxicity: A Call for Revisiting Drug Dosing in Oncology.
Fiche du document
1 juin 2022
- doi: 10.1210/endocr/bqac058
- issn: 0013-7227
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1210/endocr/bqac058
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/35560216
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1945-7170
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_FFB3F9CC400F6
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Citer ce document
B.C. Özdemir et al., « Sex and Gender Differences in Anticancer Treatment Toxicity: A Call for Revisiting Drug Dosing in Oncology. », Serveur académique Lausannois, ID : 10.1210/endocr/bqac058
Métriques
Partage / Export
Résumé
The practice of oncology has dramatically changed in the last decade with the introduction of molecular tumor profiling into routine tumor diagnostics and the extraordinary progress in immunotherapies. However, there remains an unmet need to explore personalized dosing strategies that take into account the patient's sex and gender to optimize the balance between efficacy and toxicity for each individual patient. In this mini-review, we summarize the evidence on sex and gender differences in toxicity of anticancer therapies and present data on dose reduction and dose discontinuation rates for selected chemotherapies and targeted therapies. Finally, we propose the investigation of body composition (specifically fat-free muscle mass) as a viable approach for personalized treatment dosage.